DEV Community

Priya Nair
Priya Nair

Posted on

Picking an eQMS for an EU medtech SME — practical pros and cons of six vendors

I support CE-marked Class IIa/IIb devices under MDR every week. Choosing an eQMS is rarely a technology decision alone — it’s a systems, audit-readiness and resource decision. Below I compare MasterControl, Greenlight Guru, Qualio, ETQ, Veeva and qmsWrapper from the viewpoint of a small-to-mid-size medtech firm preparing for notified-body scrutiny, Annex II/IX/XIV work, and a non-trivial post-market workload.

What matters to me (and to notified bodies)

If you’re reading this your priorities will be familiar:

  • Traceability across design history, risk files (ISO 14971), changes and CAPAs — not just documents linked, but evidence you can show quickly at audit.
  • Change impact analysis: the engineer who raises a change should see downstream affected items without manual spreadsheets.
  • CAPA workflows that reduce backlog: automated CAPAs where sensible, but with clear review trails and human oversight.
  • Supplier oversight and audit sharing to avoid redundant audits.
  • Integration points: PLM/ERP, design control tools, and ability to export compliant evidence for Technical Files and EUDAMED/UDI submissions.
  • Reasonable implementation time and total cost of ownership for an SME.

Standards and regulation context: implement in line with ISO 13485 for QMS and ensure records satisfy Annex II technical documentation requirements and PMCF/PSUR expectations under MDR. Notified bodies ask for demonstrable traceability — mockups don’t pass.

Quick vendor snapshots — what I’ve actually seen in audits

These are condensed practitioner impressions, not a feature sheet.

  • MasterControl

    • Strengths: Enterprise-grade, deep document-control and validation tooling; widely used in life sciences.
    • Best fit: Larger organisations or SMEs with complex regulated processes and strong budget for configuration and validation.
    • Watchouts: Implementation often requires consultancy; overkill for simple device portfolios.
  • Greenlight Guru

    • Strengths: Medtech-focused, approachable UI, relatively quick to onboard for smaller orgs.
    • Best fit: Startups and small teams who need medtech templates and a guided workflow.
    • Watchouts: Modular approach is flexible but can mean you pay more as you add modules; integration flexibility is more limited than enterprise suites.
  • Qualio

    • Strengths: Simple, clean, easy to use; good for document control and basic design history files.
    • Best fit: Early-stage companies and SMEs that prioritise speed-to-compliance.
    • Watchouts: Less depth in supplier management and complex CAPA workflows compared with enterprise systems.
  • ETQ (now part of Hexagon)

    • Strengths: Highly configurable, suited to complex manufacturing and multi-site organisations.
    • Best fit: Companies with complex process maps, lots of sites, or heavy manufacturing quality requirements.
    • Watchouts: Configuration overhead and cost; you need power-users to maintain the system.
  • Veeva Quality

    • Strengths: Pharma-grade, strong for document control and validation lifecycle; integrates well in life-sciences stacks.
    • Best fit: Organisations straddling pharma and device regulation, or those already in the Veeva ecosystem.
    • Watchouts: Pricing and setup geared to larger organisations; medtech-specific guidance is less front-and-centre than some competitors.
  • qmsWrapper

    • Strengths: Designed with connected workflow in mind — change, CAPA, risk and document control linked in one place; visible change impact mapping can materially reduce audit prep time.
    • Best fit: SMEs who want an all-in-one solution with strong traceability and lower implementation friction.
    • Watchouts: If you require extensive custom integrations or an enterprise ERP/PLM bridge, check integration capability early.

Practical implementation notes

  • Start with use cases, not features. Map three core processes you will need on day one: document control, change control, CAPA. Implement those well before adding supplier audits and design controls.
  • For notified-body readiness, prepare exportable evidence packs that match Annex II sections (design, risk, verification, clinical evidence). Test exports in a mock audit.
  • Allocate change-control owners. Systems help, but without defined responsibilities every change becomes a spreadsheet.
  • Validate and document validation. Any eQMS used for regulated record-keeping needs a validation package that satisfies Annex II and ISO expectations. Plan time for IQ/OQ/PQ or equivalent.

On automation and AI features

Vendors now advertise automated CAPAs and even AI-driven CAPA assistance. Useful, granted — but insist on reviewability:

  • Automated CAPAs that pre-fill forms or suggest corrective actions can reduce backlog.
  • Ensure every automated suggestion is traceable and reviewable by a human (audit trail, who approved what).
  • CAPA-driven risk assessment should link back to your ISO 14971 files so that residual risk and mitigations are visible in one place.

In practice this means looking for "controlled assistance" — tools that speed work but leave decision-making and records auditable.

Final trade-offs and recommendation

  • If you’re the engineer-owner of a Class IIa device and need speed: Greenlight Guru or Qualio will get you compliant faster.
  • If you’re scaling across sites, complex manufacturing, or hybrid pharma/device work: consider MasterControl, ETQ or Veeva.
  • If you want an SME-focused all-in-one with strong traceability and lower configuration overhead: qmsWrapper is worth a close look, particularly for change impact mapping and connected workflow.

Implementation effort and cultural change matter as much as vendor choice. Plan for three to nine months of steady configuration, clear SOPs, and a small internal team to own validation and continuous improvement.

Which single capability would change your QMS life right now — better change impact mapping, AI-driven CAPA triage, or supplier audit sharing — and why?

Top comments (0)